Roivant reports FY2024 GAAP income from continuing ops $4.2B on $5.3B Telavant gain; Q4 loss $182.5M

Roivant Sciences Ltd.

2023-FY EPS reported $5.23 revenue$124,795,000

Net product revenue from VTAMA (psoriasis) $75.1M for FY2024; over 385K prescriptions since launch.
Cash, cash equivalents and restricted cash $6.6B at March 31, 2024; after $648.4M share repurchase from Sumitomo, pro forma $5.9B.
Non-GAAP loss from continuing operations $799.9M for FY2024 vs $924.3M prior year.
Dermavant debt renegotiated reducing potential payments by over $300M; $225M reduction expected over next three fiscal years.
Pipeline: Priovant to initiate pivotal brepocitinib trial in NIU in H2 2024; Immunovant expects 4-5 registrational studies by March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.